Episodes (Page 2)
✨
Paul Romness explains OS Therapies' HER2-targeted immunotherapy for pulmonary osteosarcoma.
Paul Romness
✨
Benjamin Oakes discusses Scribe Therapeutics' CRISPR and epigenetic editing tools.
Benjamin Oakes
✨
Rachel Haurwitz on Caribou Biosciences' off-the-shelf CRISPR CAR-T therapies.
✨
Editors' Roundtable offers a 2025 retrospective of the life science industry.
✨
Dr. Norman Putzki discusses Novartis' Itvisma for SMA treatment.
Norman Putzki
✨
Alexander Cryer on reprogramming tumor microenvironment with mRNA LNPs.
✨
Paul Perreault shares insights on patient-driven culture and leadership.
Paul Perreault
✨
Dr. Arun Upadhyay discusses Ocugen's modifier gene therapy for retinal disorders.
✨
Aliya Omer on advancing hematology and cell therapy at AstraZeneca.
Aliya Omer
✨
Brian Culley discusses Lineage's allogeneic cell therapy for SCI and blindness.
✨
Thorsten Gorba on AI/ML for iPSC quality assessment at Aspen Neuroscience.
Thorsten Gorba
✨
Mike Quigley discusses Sanofi's Genomic Medicine Unit vision.
Mike Quigley
✨
Sanjeev Luther on Ernexa's engineered iMSCs for cancer and autoimmune disease.
Sanjeev Luther
✨
Daniela Drago on FDA/CBER shifts impacting CGT development.
Daniela Drago
✨
Yuanhao Qu introduces CRISPR-GPT, an AI-driven system for genetic experiments.
Yuanhao Qu
✨
Bambi Grilley on barriers and access in pediatric CGTs.
Bambi Grilley
✨
Monika Swietlicka on defining product roles and navigating FDA approval.
Monika Swietlicka
✨
Dr. Will Chou discusses gene therapy for frontotemporal dementia (FTD).
Will Chou
✨
Kaye Spratt emphasizes early and continuous FDA engagement for CGTs.
✨
Nate Fernhoff on Orca Bio's safer stem cell therapies for blood cancers.
Nate Fernhoff